09/ 724,897

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS 12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 13	APR 26	PROMT: New display field available
NEWS 14	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 15	APR 26	LITALERT now available on STN
NEWS 16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:43:16 ON 09 MAY 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

09/ 724,897

FILE 'REGISTRY' ENTERED AT 10:44:16 ON 09 MAY 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 MAY 2004 HIGHEST RN 680859-76-1
DICTIONARY FILE UPDATES: 7 MAY 2004 HIGHEST RN 680859-76-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\09724897.str





chain nodes :
11 12 13 14 15 16 17 18
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
2-14 3-12 4-11 12-13 14-15 14-16 16-18 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
1-2 1-6 2-3 3-12 4-11 14-15 14-16
exact bonds :
2-14 3-4 4-5 12-13 16-18 16-17
normalized bonds :
5-6 5-7 6-10 7-8 8-9 9-10
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 10:44:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2636 TO ITERATE

100.0% PROCESSED 2636 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L2 9 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.84

FILE 'CAPLUS' ENTERED AT 10:44:45 ON 09 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 May 2004 VOL 140 ISS 20
FILE LAST UPDATED: 7 May 2004 (20040507/ED)

This file contains CAS Registry Numbers for easy and accurate

substance identification.

```
=> s l2
L3              5 L2

=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y
```

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:80465 CAPLUS
DOCUMENT NUMBER: 140:139471
TITLE: Preparation of of quinazolinone-like derivatives to treat cellular proliferative diseases
INVENTOR(S): Bergnes, Gustave; Smith, Whitney W.; Yao, Bing; Morgans, David J., Jr.; MacDonald, Andrew
PATENT ASSIGNEE(S): Cytokinetics, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009036	A2	20040129	WO 2003-US23319	20030723

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-398224P P 20020723
OTHER SOURCE(S): MARPAT 140:139471
AB The invention relates to quinazolinone-like derivs. that are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation. Preparation of 3-Benzyl-7-chloro-2-(3-benzyl-2-oxohexahydropyrimidin-4-yl)-3H-quinazolin-4-one is included.
IT **651323-46-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinone derivs. to treat cellular proliferative diseases)
RN 651323-46-5 CAPLUS
CN Carbamic acid, [3-amino-3-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:931177 CAPLUS
DOCUMENT NUMBER: 140:5063
TITLE: 2-[1-(Imidazol-1-yl)alkyl]-3H-quinazolin-4-one derivatives, pharmaceutical compositions containing them, and methods of their use as KSP kinesin inhibitors for the treatment of cellular proliferative diseases
INVENTOR(S): Feng, Bainian; Bergnes, Gustave; Morgans, David J. C., Jr.; Dhanak, Dashyant; Knight, Steven David; Darcy, Michael Gerard
PATENT ASSIGNEE(S): Cytokinetics, Inc., USA; Smithkline Beecham Corporation
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097053	A1	20031127	WO 2003-US14787	20030508

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004077668 A1 20040422 US 2003-435069 20030508
PRIORITY APPLN. INFO.: US 2002-379531P P 20020509
OTHER SOURCE(S): MARPAT 140:5063
GI



AB Compds. useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP (kinesin-like spindle protein), and especially
human KSP, are disclosed (no data). In particular, compds. I are claimed

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
[wherein: R1 = H, (un)substituted alkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; R2, R2' = H, (un)substituted alkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or R2R2' = (un)substituted 3- to 7-membered ring; R5, R6, R7, R8 = H, (un)substituted alkyl or alkoxy, halo, OH, NO2, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, (un)substituted aryl, aryloxy, heteroaryl, or heteroaryloxy; R9 = H, (un)substituted alkyl, aryl, aralkyl, or heteroaryl; R10, R10', R11, R11' = H, (un)substituted alkyl, aryl, or aralkyl; or R10'R11' = pi bond; including single and mixed stereoisomers and pharmaceutically acceptable salts and/or solvates]. Approx. 60 compds. I are described in examples. Compds. I having (R)-configuration at the stereogenic center bearing R2 are preferred for reasons of greater potency than the (S)-isomers. For instance, 2-(1-amino-2-methylpropyl)-3-benzyl-7-chloro-3H-quinazolin-4-one underwent a sequence of N-alkylation at amino with BrCH2CH(OMe)2 and K2CO3 (59%), amidation of the resultant secondary amine with PhCOCl and Et3N (54%), and deprotection/cyclocondensation with NH4OAc in refluxing AcOH (23%) to give invention compd. II. Compds. I are said to be active against human ovarian cancer cells SKOV3 in vitro. Visual inspection revealed that the compds. caused cell cycle arrest in the prometaphase stage of mitosis; DNA was condensed and spindle formation had initiated, but arrested cells uniformly displayed monopolar spindles, indicating that there was an inhibition of spindle pole body sepn.
IT **336113-57-6 336119-88-1**, 2-(1-Amino-2-methylpropyl)-3-benzyl-7-chloro-3H-quinazolin-4-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of (imidazolylalkyl)quinazolinone derivs. as KSP kinesin inhibitors for the treatment of cellular proliferative diseases)
RN 336113-57-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-1-amino-2-methylpropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336119-88-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-amino-2-methylpropyl)-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:678784 CAPLUS
DOCUMENT NUMBER: 139:214481
TITLE: Syntheses of enantiomerically pure quinazolinones
INVENTOR(S): Bergnes, Gustav; Ha, Edward; Yiannikourous, George; Kalaritis, Panos; Yonce, Brandon E.; Welday, Kurt Alan, Jr.
PATENT ASSIGNEE(S): Cytokinetics, Inc., USA; SmithKline Beecham Corp.
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070701	A2	20030828	WO 2003-US4713	20030214
WO 2003070701	A3	20031016		
WO 2003070701	B1	20031218		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004067969	A1	20040408	US 2003-366828	20030214

PRIORITY APPLN. INFO.: US 2002-357244P P 20020215
US 2002-380746P P 20020514
OTHER SOURCE(S): MARPAT 139:214481
GI



I

AB The present invention provides intermediates, synthetic methods and novel quinazolinone (shown as I; e.g. (R)-N-(3-aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide) compns. of matter, which are inhibitors of the mitotic

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

kinesin KSP (no data) and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation (no data); only the compds., compns. of matter and synthetic methods are claimed. The method comprises contacting HO2CCH(R2)NHX (R2 = oxaalkyl or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl; X = H, protecting group (e.g. Boc, CBZ, phthalide, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl); e.g. valine) with iso-Bu chloroformate followed by contacting the resulting product with (un)substituted 2-aminobenzoic acids to give I. Eight example prepns. of I are included. For example, (S)-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]carbamic acid tert-Bu ester was prepd. starting from N-Boc-L-valine and involving intermediates 2-{[2-[(tert-butoxycarbonyl)amino]-L-3-methylbutyryl]amino}-4-chlorobenzoic acid, (S)-[1-(7-chloro-4-oxo-4H-benzo[d][1,3]oxazin-2-yl)-2-methylpropyl]carbamic acid tert-Bu ester, (S)-[1-[[(2-benzylcarbamoyl-5-chlorophenyl)imino]methyl]-2-methylpropyl]carbamic acid tert-Bu ester (in mixt. with the final product). In the key step, to 2-[[2-[(tert-butoxycarbonyl)amino]-L-3-methylbutyryl]amino]-4-chlorobenzoic acid was added 13.2 mL (0.1 mol) of iso-Bu chloroformate over 15 min (internal temp. 5°) followed by the addn. of 11.1 mL (0.1 mol) of anhyd. N-methylmorpholine over 15 min at 0°; the mixt. was stirred for an addnl. hour at 0° to give (S)-[1-(7-chloro-4-oxo-4H-benzo[d][1,3]oxazin-2-yl)-2-methylpropyl]carbamic acid tert-Bu ester. For I: R1 is H or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl; R3 is H, oxaalkyl, R9O-, R9NH- or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, or oxaalkylaryl; R4 is H or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl; R5, R6, R7 and R8 = H, hydroxy, (un)substituted alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, amino, alkylamino, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl or heteroaryl; and R9 is (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl. The compns. of matter comprise I and detectable amts. of ≥1 unreacted starting materials and/or a cyclo-dehydration reagent; they are claimed, presumably because it is important to monitor the purity of pharmaceutical compds. for the presence of such materials, which presence comprises a way of detecting use of a process of the invention.

IT **336119-88-1P**, 2-(1-Amino-2-methylpropyl)-3-benzyl-7-chloro-3H-quinazolin-4-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(resolution; syntheses of enantiomerically pure quinazolinones)

RN 336119-88-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-amino-2-methylpropyl)-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **336113-57-6P**, (R)-2-(1-Amino-2-methylpropyl)-3-benzyl-7-chloro-3H-quinazolin-4-one

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(syntheses of enantiomerically pure quinazolinones)

RN 336113-57-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-1-amino-2-methylpropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **336113-58-7P**, (S)-2-(1-Amino-2-methylpropyl)-3-benzyl-7-chloro-3H-quinazolin-4-one **587881-26-3P**, 2-(1-Amino-2-methylpropyl)-3-benzyl-7-chloro-3H-quinazolin-4-one hydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(syntheses of enantiomerically pure quinazolinones)

RN 336113-58-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-amino-2-methylpropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 587881-26-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-amino-2-methylpropyl)-7-chloro-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



●x HCl

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:935583 CAPLUS
DOCUMENT NUMBER: 136:53759
TITLE: Preparation of N-acylquinazolinonealkylamines as KSP kinesin inhibitors
INVENTOR(S): Finer, Jeffrey T.; Bergnes, Gustav; Feng, Bainian; Smith, Whitney W.; Chabala, John C.; Morgans, David J., Jr.
PATENT ASSIGNEE(S): Cytokinetics, Inc., USA
SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098278	A1	20011227	WO 2001-US13901	20010427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6545004	B1	20030408	US 2000-699047	20001024
JP 2003048881	A2	20030221	JP 2002-156766	20001026
US 6562831	B1	20030513	US 2000-724644	20001128
US 6630479	B1	20031007	US 2000-724713	20001128
EP 1296959	A1	20030402	EP 2001-932769	20010427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011898	A	20030513	BR 2001-11898	20010427
JP 2004501140	T2	20040115	JP 2002-504234	20010427
ZA 2002010133	A	20030617	ZA 2002-10133	20021213
NO 2002006172	A	20030220	NO 2002-6172	20021220
US 2004023996	A1	20040205	US 2003-312323	20030815

PRIORITY APPLN. INFO.: US 2000-213104P P 20000621
US 2000-699047 A 20001024
US 1999-198253P P 19991027
JP 2001-533122 A3 20001026
WO 2001-US13901 W 20010427

OTHER SOURCE(S): MARPAT 136:53759
GI

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



II

AB R1CR2R2'NRR4 [I; R = H, COR3, SO2R3', CH2R3''; R1 = (un)substituted 3,4-dihydro-4-oxoquinazolin-2-yl; R2,R2' = H, (oxa)alkyl, (hetero)aryl, etc.; R3 = H, alkyl, alkoxy, (hetero)aryl, etc.; R3',R4 = H, alkyl, (hetero)aryl, etc.; R3'' = alkyl, (hetero)aryl, etc.] were prepared Thus, 2-(H2N)C6H4CO2H was amidated by PrCOCl and the cyclized product cyclocondensed with PhCH2NH2 to give, after bromination, quinazolinone II (R = Br) which was converted in 2 steps to II [R = N(COC6H4F-4)CH2CH2NMe2]. Data for biol. activity of I were given.

IT **336113-55-4P 336113-56-5P 336113-57-6P**
336113-58-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-acylquinazolinonealkylamines as KSP kinesin inhibitors)

RN 336113-55-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-1-aminopropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336113-56-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-aminopropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 336113-57-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-1-amino-2-methylpropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336113-58-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-amino-2-methylpropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **336119-87-0P 383192-88-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-acylquinazolinonealkylamines as KSP kinesin inhibitors)

RN 336119-87-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-aminopropyl)-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 383192-88-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-aminopropyl)-7-chloro-3-(phenylmethyl)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336119-87-0

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CMF C18 H18 Cl N3 O



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:319882 CAPLUS
DOCUMENT NUMBER: 134:326543
TITLE: Methods and compositions utilizing quinazolinones as KSP kinesin modulators
INVENTOR(S): Finer, Jeffrey T.; Bergnes, Gustave; Feng, Bainian; Smith, Whitney W.; Chabala, John C.
PATENT ASSIGNEE(S): Cytokinetics, Inc., USA
SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030768	A1	20010503	WO 2000-US29585	20001026
WO 2001030768	C2	20020815		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000015110	A	20020702	BR 2000-15110	20001026
EP 1226129	A1	20020731	EP 2000-976656	20001026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003048881	A2	20030221	JP 2002-156766	20001026
JP 2003512461	T2	20030402	JP 2001-533122	20001026
NZ 518480	A	20040227	NZ 2000-518480	20001026
US 6562831	B1	20030513	US 2000-724644	20001128
US 6630479	B1	20031007	US 2000-724713	20001128
ZA 2002002930	A	20021028	ZA 2002-2930	20020415
NO 2002001907	A	20020607	NO 2002-1907	20020423
ZA 2002010133	A	20030617	ZA 2002-10133	20021213

PRIORITY APPLN. INFO.:
US 1999-198253P P 19991027
US 2000-213104P P 20000621
US 2000-699047 A1 20001024
JP 2001-533122 A3 20001026
WO 2000-US29585 W 20001026

OTHER SOURCE(S): MARPAT 134:326543
GI

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

II

AB Quinazolinones (I) [wherein R1 = H, alkyl, (hetero)aryl, or (un)substituted alkyl(hetero)aryl; R2 and R2a = independently H or (un)substituted (oxa)alkyl, (hetero)aryl, or alkyl(hetero)aryl; Y = NR4COR3, NR4SO2R3a, NR4CH2R3b, or NHR4; R3 = H, oxaalkyl, or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, oxaalkylaryl, ether, or amino; R3a = H or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, or amino; R3b = (un)substituted alkyl, (hetero)aryl, or alkyl(hetero)aryl; R4 = H or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, or alkylene; R5-R8 = independently H, (fluoro)alkyl, alkoxy, halo, NO2, dialkylamino, alkylsulfonyl, alkylsulfonamido(alkyl or aryl), alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, or (hetero)aryl] were prepared by conventional and solid phase combinatorial synthetic methods as KSP kinesin inhibitors for treatment of cellular proliferative diseases. For example, II was synthesized in a 6-step sequence involving (1) amidation of anthranilic acid with butyryl chloride (65%), (2) cyclization to give 2-propyl-3,1-[4H]benzoxazin-4-one (62%), (3) treatment with PhCH2NH2 to give 2-propyl-3-benzylquinazolin-4-one (67%), bromination (92%), addition of N,N-dimethylethylenediamine (55%), and (6) amidation with p-fluorobenzoyl chloride (65%). I are useful for treating cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders, and inflammation (no data). Methods of screening for compds. that will bind to a KSP kinesin or are modulators of KSP kinesin activity are also disclosed.

IT **336113-55-4P 336113-56-5P 336113-57-6P 336113-58-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolinone KSP kinesin modulators via conventional and solid phase combinatorial synthetic methods)

RN 336113-55-4 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-1-aminopropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 336113-56-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-aminopropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336113-57-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1R)-1-amino-2-methylpropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336113-58-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(1S)-1-amino-2-methylpropyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **336119-87-0P 336119-88-1P**
RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinone KSP kinesin modulators via conventional and solid phase combinatorial synthetic methods)

RN 336119-87-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-aminopropyl)-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 336119-88-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-amino-2-methylpropyl)-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT